Interestingly, ERK5 inhibition or MEK5 genetic deletion also sensitized NSCLC KRAS mutated A549 cells to TRAIL cytotoxicity, a model where TRAIL induces cancer progression, invasion and metastasis instead of activating apoptosis [50, 52]. Here, KRAS is linked to non-small cell lung carcinoma.